SPY457.87+7.37 1.64%
DIA347.27+6.81 2.00%
IXIC15,363.62+109.57 0.72%

HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $10

HC Wainwright & Co. maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and raises the price target from $6 to $10.

Benzinga · 11/11/2021 06:47
HC Wainwright & Co. maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and raises the price target from $6 to $10.